BRPI1006266A2 - adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato - Google Patents
adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvatoInfo
- Publication number
- BRPI1006266A2 BRPI1006266A2 BRPI1006266-1A BRPI1006266A BRPI1006266A2 BR PI1006266 A2 BRPI1006266 A2 BR PI1006266A2 BR PI1006266 A BRPI1006266 A BR PI1006266A BR PI1006266 A2 BRPI1006266 A2 BR PI1006266A2
- Authority
- BR
- Brazil
- Prior art keywords
- adsorbate
- dosage form
- preparing
- relates
- api
- Prior art date
Links
- 239000002156 adsorbate Substances 0.000 title abstract 9
- 239000002552 dosage form Substances 0.000 title abstract 8
- 238000004519 manufacturing process Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 abstract 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002297 fenofibrate Drugs 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000012454 non-polar solvent Substances 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato a presente invenção pertence ao campo da indústria farmacêutica e refere-se às formas de dosagem compreendendo ingredientes farmaceuticamente ativos (api) como tadalafil, sinvastatina, fenofibrato e lovastatina que são praticamente insolúveis em água, adsorvidos em um veículo. além disso, ela refere-se a um adsorvato compreendendo api sendo praticamente insolúvel em água e a um processo para a preparação do dito adsorvato com solvente(s) não polar(es) tais como hidrocarboneto clorado, éter diisopropílico e hexano. além disso, a invenção refere-se a um processo para a preparação da forma de dosagem, bem como ao uso do adsorvato para a preparação da forma de dosagem. além disso, ela refere-se à forma de dosagem para uso no tratamento de disfunção erétil, infecções pelo vírus da imunodeficiência humana (hiv) e/ou síndrome da imunodeficiência adquirida (aids).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09005047.7 | 2009-04-06 | ||
| EP09005047A EP2238979A1 (en) | 2009-04-06 | 2009-04-06 | Active pharmaceutical ingredient adsorbed on solid support |
| PCT/EP2010/054526 WO2010115886A1 (en) | 2009-04-06 | 2010-04-06 | Active pharmaceutical ingredient adsorbed on solid support |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006266A2 true BRPI1006266A2 (pt) | 2019-03-26 |
Family
ID=41210841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006266-1A BRPI1006266A2 (pt) | 2009-04-06 | 2010-04-06 | adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120088774A1 (pt) |
| EP (2) | EP2238979A1 (pt) |
| JP (1) | JP2012522825A (pt) |
| CN (1) | CN102448460A (pt) |
| AU (1) | AU2010233809B2 (pt) |
| BR (1) | BRPI1006266A2 (pt) |
| CA (1) | CA2757988C (pt) |
| EA (1) | EA031818B1 (pt) |
| MX (1) | MX2011010563A (pt) |
| WO (1) | WO2010115886A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| RU2013141446A (ru) | 2011-02-10 | 2015-03-20 | Синтон Бв | Фармацевтическая композиция, содержащая тадалафил и циклодекстрин |
| WO2012107090A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Granulated composition comprising tadalafil and a disintegrant |
| EP2672960A1 (en) * | 2011-02-10 | 2013-12-18 | Synthon BV | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| WO2012107092A1 (en) | 2011-02-10 | 2012-08-16 | Synthon Bv | Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| JP2014521745A (ja) * | 2011-08-16 | 2014-08-28 | メルク・シャープ・アンド・ドーム・コーポレーション | 安定した非晶質分散体を調製するための無機マトリックスと有機ポリマーの組み合わせの使用 |
| SI3172207T1 (sl) | 2014-07-23 | 2019-06-28 | Krka D.D., Novo Mesto | Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila |
| EP3233059A1 (en) | 2014-12-19 | 2017-10-25 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
| CN105380908B (zh) * | 2015-12-09 | 2018-08-10 | 河北大学 | 一种丁苯酞药物复合物及其制备方法和缓释制剂 |
| CA3036897C (en) | 2016-10-25 | 2021-11-16 | The Procter & Gamble Company | Fibrous structures |
| US10538881B2 (en) | 2016-10-25 | 2020-01-21 | The Procter & Gamble Company | Fibrous structures |
| WO2020012243A2 (en) * | 2018-07-09 | 2020-01-16 | Abbott Laboratories Gmbh | Pharmaceutical composition containing a peptide |
| CN109528675B (zh) * | 2018-12-31 | 2020-12-22 | 杭州康本医药科技有限公司 | 一种他达拉非肠溶片剂及其制备方法 |
| CN113476408A (zh) * | 2021-07-23 | 2021-10-08 | 兆科药业（广州）有限公司 | 一种苯丁酸甘油酯颗粒剂及其制备方法与应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA72698B (en) * | 1972-02-03 | 1973-09-26 | Liebenberg R W | Method of preparing medicinal compositions |
| EP0129893B1 (en) | 1983-06-28 | 1991-09-04 | Takeda Chemical Industries, Ltd. | Ground mixture |
| JPS63119426A (ja) * | 1986-11-06 | 1988-05-24 | Mitsubishi Kasei Corp | 肝疾患治療薬組成物 |
| JP3886171B2 (ja) * | 1995-04-28 | 2007-02-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 薬剤組成物 |
| GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| WO1996039126A2 (en) * | 1995-06-06 | 1996-12-12 | Warner-Lambert Company | Ranitidine salts on magnesium trisilicate as an adsorbate |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| OA12625A (en) * | 2001-06-22 | 2006-06-12 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug. |
| EP1474123A1 (en) * | 2002-01-03 | 2004-11-10 | LEK Pharmaceuticals D.D. | Controlled release pharmaceutical formulation containing venlafaxine |
| BRPI0413277A (pt) * | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
| US20070298108A1 (en) * | 2004-03-01 | 2007-12-27 | Peter Svete | Pharmaceutical Formulation |
| WO2005116030A1 (en) * | 2004-05-31 | 2005-12-08 | Matrix Laboratories Ltd | A process for the preparation of tadalafil |
| KR20070072891A (ko) | 2004-11-02 | 2007-07-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타달라필 결정형 및 이의 제조 방법 |
| JPWO2006080312A1 (ja) * | 2005-01-25 | 2008-06-19 | 興和株式会社 | 吸着多孔体の製造法 |
| US7417044B2 (en) | 2005-02-25 | 2008-08-26 | Teva Pharmaceutical Industries Ltd. | Tadalafil having a large particle size and a process for preparation thereof |
| EP1843770B1 (en) | 2005-08-29 | 2008-06-18 | Teva Pharmaceutical Industries Ltd | Solid particulate tadalafil having a bimodal particle size distribution |
| KR101140110B1 (ko) | 2006-07-07 | 2012-06-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타달라필 및 하나 이상의 담체를 포함하는 고체 조성물 |
| US20110097414A1 (en) | 2007-02-26 | 2011-04-28 | Sandal Roshan Lal | Pharmaceutical compositions comprising adsorbate of fenofibrate |
| US20090098211A1 (en) * | 2007-04-25 | 2009-04-16 | Ilan Zalit | Solid dosage forms |
| EP2072042A1 (en) * | 2007-12-21 | 2009-06-24 | Lek Pharmaceuticals D.D. | Active pharmaceutical ingredient on solid support, amorphous and with improved solubility |
-
2009
- 2009-04-06 EP EP09005047A patent/EP2238979A1/en not_active Ceased
-
2010
- 2010-04-06 JP JP2012503994A patent/JP2012522825A/ja active Pending
- 2010-04-06 EA EA201101432A patent/EA031818B1/ru not_active IP Right Cessation
- 2010-04-06 MX MX2011010563A patent/MX2011010563A/es active IP Right Grant
- 2010-04-06 AU AU2010233809A patent/AU2010233809B2/en not_active Ceased
- 2010-04-06 WO PCT/EP2010/054526 patent/WO2010115886A1/en not_active Ceased
- 2010-04-06 CN CN2010800227528A patent/CN102448460A/zh active Pending
- 2010-04-06 BR BRPI1006266-1A patent/BRPI1006266A2/pt not_active IP Right Cessation
- 2010-04-06 US US13/263,051 patent/US20120088774A1/en not_active Abandoned
- 2010-04-06 EP EP10713900A patent/EP2416775A1/en not_active Withdrawn
- 2010-04-06 CA CA2757988A patent/CA2757988C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010115886A1 (en) | 2010-10-14 |
| CA2757988C (en) | 2018-06-19 |
| AU2010233809B2 (en) | 2015-03-12 |
| CN102448460A (zh) | 2012-05-09 |
| EA031818B1 (ru) | 2019-02-28 |
| MX2011010563A (es) | 2012-01-20 |
| US20120088774A1 (en) | 2012-04-12 |
| EA201101432A1 (ru) | 2012-04-30 |
| EP2238979A1 (en) | 2010-10-13 |
| EP2416775A1 (en) | 2012-02-15 |
| CA2757988A1 (en) | 2010-10-14 |
| AU2010233809A1 (en) | 2011-11-10 |
| JP2012522825A (ja) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006266A2 (pt) | adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato | |
| MX2018005708A (es) | Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7. | |
| GT201200158A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
| CU20160187A7 (es) | (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| CL2017002709A1 (es) | Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr | |
| CL2013001339A1 (es) | Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih. | |
| BR112015000615A8 (pt) | Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| SV2010003581A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| CL2015001756A1 (es) | Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion. | |
| BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
| GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| EP4309736A3 (en) | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide | |
| CL2013001935A1 (es) | Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer. | |
| NZ601319A (en) | Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2h-pyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| BRPI0618239A8 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos | |
| UY37705A (es) | Nuevos derivados de pirazol bicíclicos | |
| ES2524385R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CL2013002129A1 (es) | Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras. | |
| ES2555557R1 (es) | Fármaco y uso para preparar un medicamento destinado a la prevención de la infección del VIH y al tratamiento de enfermedades causadas por el VIH, incluido el SIDA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2561 DE 2020-02-04 |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |